Table 3.
Properties of test drugs and compounds used in the present study
| Drug/compound | Selectivity | Dose tested (mg/kg, i.v.) | Expected acute behavioral effects1 | βCCT sensitive |
|---|---|---|---|---|
| alprazolam | none | 0.1 | Rest/sleep posture | No |
| Observable ataxia | Yes | |||
| 1.0 | Deep sedation, | Yes | ||
| Observable ataxia | Yes | |||
| Midazolam2 | none | 0.1 | Rest/sleep posture | No |
| Observable ataxia | Yes | |||
| 1.0 | Deep sedation | Yes | ||
| Observable ataxia | Yes | |||
| zolpidem | α1GABAA preferential affinity | 3.0 | Increased tac/oral | Yes |
| Observable ataxia | Yes | |||
| 5.6 | Deep sedation | Yes | ||
| Decreased tac/oral | No | |||
| HZ-166 | α2/α3GABAA preferential efficacy | 10.0 | Rest/sleep posture | No |
| Decreased tac/oral | No | |||
| βCCT | α1GABAA Preferential affinity | 1.0 | No effect | N/A |
| 3.0 | No effect | N/A |
1.
Based on quantitative behavioral observation in rhesus monkeys (Duke et al., 2018; 2020).
2.
Midazolam results with βCCT are predicted but not tested. Effects of midazolam alone were based on unpublished data. All other predictions based on Duke et al. (2018; 2020).